Impact of physiological, and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans

被引:100
作者
Hurst, Susan [1 ]
Loi, Cho-Ming [1 ]
Brodfuehrer, Joanne [1 ]
El-Kattan, Ayman [1 ]
机构
[1] Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Ann Arbor, MI 48105 USA
关键词
absorption; bioavailability; biopharmaceutical factors; first-pass effect; metabolism; physicochemical factors; species differences;
D O I
10.1517/17425225.3.4.469
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The onset, intensity and duration of therapeutic response to a compound depend on the intrinsic pharmacological activity of the drug and pharmacokinetic factors related to its absorption, distribution, metabolism and elimination that are inherent to the biological system. The process of drug transfer from the site of administration to the systemic circulation and the interspecies factors that impact this process are the scope of this review. In general, the factors that influence oral drug bioavailability via absorption and metabolism can be divided into physicochemical/biopharmaceutical and physiological factors. Physicochemical and biopharmaceutical factors that influence permeability and solubility tend to be species independent. Although there are significant differences in the anatomy and physiology of the gastrointestinal tract, these are not associated with significant differences in the rate and extent of drug absorption between rats and humans. However, species differences in drug metabolism in rats and humans did result in significant species differences in bioavailability. Overall, this review provides a better understanding of the interplay between drug physicochemical/biopharmaceuticaI factors and species differences/similarities in the absorption and metabolism mechanisms that affect oral bioavailability in rats and humans. This will enable a more rational approach to perform projection of oral bioavailability in human using available rat in vivo data.
引用
收藏
页码:469 / 489
页数:21
相关论文
共 189 条
[61]   EFFECTS OF ANTACIDS ON THE CLINICAL PHARMACOKINETICS OF DRUGS - AN UPDATE [J].
GUGLER, R ;
ALLGAYER, H .
CLINICAL PHARMACOKINETICS, 1990, 18 (03) :210-219
[62]   Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta [J].
Hakkola, J ;
Pasanen, M ;
Hukkanen, J ;
Pelkonen, O ;
Maenpaa, J ;
Edwards, RJ ;
Boobis, AR ;
Raunio, H .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (04) :403-411
[63]   Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy [J].
Hakkola, J ;
Raunio, H ;
Purkunen, R ;
Pelkonen, O ;
Saarikoski, S ;
Cresteil, T ;
Pasanen, M .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (02) :379-383
[64]  
Hanano M, 1993, Nihon Rinsho, V51, P851
[65]   RATE-LIMITING BARRIERS TO INTESTINAL DRUG ABSORPTION - A REVIEW [J].
HAYTON, WL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1980, 8 (04) :331-334
[66]   Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides [J].
He, YL ;
Murby, S ;
Warhurst, G ;
Gifford, L ;
Walker, D ;
Ayrton, J ;
Eastmond, R ;
Rowland, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (05) :626-633
[67]   THEORETICAL-MODEL OF GASTROINTESTINAL ABSORPTION OF LEAD [J].
HEALY, MA .
JOURNAL OF CLINICAL AND HOSPITAL PHARMACY, 1984, 9 (03) :257-261
[68]  
Hebel R., 1986, ANATOMY EMBRYOLOGY L
[69]   Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies [J].
Hellriegel, ET ;
Bjornsson, TD ;
Hauck, WW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) :601-607
[70]  
Hendriksen BA, 2003, AAPS PHARMSCI, V5